Contents

DRCR.net PROTOCOL T: Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

June 1, 2016

Clinical trial

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW.

Ophthalmology. 2016 Jun;123(6):1351-9.
Full text | Metrics.

Main finding: At 2 years, VA outcomes were similar for eyes with baseline VA 20/32-20/40 (6/9.5 – 6/12). In those with worse VA, VA outcomes were superior in Aflibercept vs bevacizumab. Higher APTC event rates with ranibizumab over 2 years was noted

 

  • Purpose: To compare the effectiveness of 3 commonly used anti–vascular endothelial growth factor agents in Diabetic Macular Edema
  • Study type: Randomized controlled trial
  • Condition: Diabetic Macular Edema

Participants: Type 1 or 2 DM, Ci-DME , VA 20/32-20/320 (6/9.5-6/96)

 

  • n=660

 

Intervention:

 

Regime:

 

  • Intravitreal injections up to monthly. Focal/grid laser added from 6 months if persistent DME.

 

Groups:

 

  • Group 1: Aflibercept 2mg
  • Group 2: Bevacizumab 1.25mg
  • Group 3: Ranibizumab 0.3mg

VA outcomes were similar among treatment groups for eyes with baseline VA 20/32-20/40

 

Among eyes with worse baseline VA, aflibercept had superior 2-year VA outcomes vs bevacizumab. Superiority of aflibercept over ranibizumab noted at 1 year was not identified at 2 years.

Outcomes Groups Aflibercept Bevacizumab Ranibizumab
VA letter score gain Overall 12.8 10.0 12.3
Worse baseline VA (20/50-20/32) 18.3 13.3 16.1
Better baseline VA (20/32-20/40) 7.8 6.8 8.6

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed